PRODUCT OF THE WEEK: Caregivers love this pill box, as do patients and professionals. Simply fill it once a month. Roomy, simple, ingenious.
Caring for someone with Alzheimer’s is demanding enough. Now, instead of traveling for hours of infusions, families can turn to Leqembi IQLIK—a once-weekly injection approved by the FDA that makes treatment simpler, safer, and closer to home.
They’re not just pills—they’re precision infusions designed to slow Alzheimer’s at its source. See UCLA’s cutting-edge Amyloid Immunotherapy Care Program, and what it feels like to begin treatment with Leqembi (lecanemab) and Kisunla (donanemab).
Leqembi, the first Alzheimer’s-modifying drug, is a giant step forward—but how many people are getting it, and what does it really cost the average American? We dig into the numbers, the barriers, and the path forward.
FDA approves a newly recommended dosing schedule for Kisunla (Donanemab). It’s significantly safer due to lowered ARIA-E rates, which has been the main problem with these drugs.
Lecanemab (marketed as Leqembi) is today’s top Alzheimer’s drug. Why does equitable access to this drug remain a significant challenge? What needs to be done?
MEDICATION VIDEO:
How do you know when Alzheimer’s meds ought to be stopped? Explore the benefits of these medications, such as improved cognition, memory, behavior, lifespan, and the stages they are most effective.
Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.
Alzheimer’s rates are on the rise. How is today’s best treatment, Leqembi (generic lecanemab) doing in the fight against it?
See why Leqembi is even more effective in males than females, at fighting Alzheimer’s.
Too much sleep and too little sleep can contribute to cognitive decline, researchers report. Learn more.
People with dementia who were consistently seen by the same General Practitioner (GP) are given fewer medicines and are less likely to be given medicines that can cause problems, according to researchers at University of Exeter. Learn more.
New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.
Researchers found in a study that people who developed dementia were more likely to have their credit rating drop at least two and a half years before the diagnosis. Some had problems managing their money up to six years before. Find out more.
Researchers find that a diet including more fruit, vegetables, beans and tea or coffee lowers the risk of developing dementia later in life. Learn more.
Did you know? Intellectual abilities are increased in the brain by an average 300% in most people ages 60-80.
Too much sleep and too little sleep can contribute to cognitive decline, researchers report. Learn more.
No spam, only news and updates.
